Search research articles
Contact Us
Filters
Showing results (281-290 of 426) with videos related to
Page
of 43
Sort By:
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
Plos One
|
November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
Geraldine Perkins, Timothy A Yap, Lorna Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Daniel C Danila, Michael J Morris, Johann S de Bono, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
European Urology
|
October 21, 2018
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies
David Olmos, Douglas Barker, Rohini Sharma, et al.
Radiology
|
November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study
Raquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
The Oncologist
|
March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Page
of 43
Search research articles
Search
Showing results (281-290 of 426) with videos related to
Sort By:
Page
of 43
European Urology
|
January 7, 2024
Safety Analyses of the Phase 3 VISION Trial of [<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Kim N Chi, Andrew J Armstrong, Bernd J Krause, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
British Journal of Cancer
|
July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L R Molife, P C Fong, L Paccagnella, et al.
Plos One
|
November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
Geraldine Perkins, Timothy A Yap, Lorna Pope, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Daniel C Danila, Michael J Morris, Johann S de Bono, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
European Urology
|
October 21, 2018
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Zafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies
David Olmos, Douglas Barker, Rohini Sharma, et al.
Radiology
|
November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study
Raquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
The Oncologist
|
March 22, 2015
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors
Chooi Peng Lee, N Jane Taylor, Gerhardt Attard, et al.
Page
of 43